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Introduction
Although current treatments for multiple myeloma (MM)
induce responses in more than 90% of patients,1 the disease
remains incurable in most of them. The pattern of relapse is
quite heterogeneous, including frequent biochemical relapses
in the absence of clinical symptoms. Although patients with
such relapses may not need therapy for a certain period of
time, they are at high risk of symptomatic progression and
therapy requirement. The current recommendation of the
International Myeloma Working Group (IMWG) is that
patients in biological relapse should not be treated until they
develop clinical symptoms,2 except in those cases with the so-
called “significant paraprotein relapse” in whom the relapse is
represented by a rate of rise or absolute level of M-protein at
which the risk is considered very high; in these cases it is rec-
ommended that myeloma therapy is restarted without delay.3
Intravenous bisphosphonates are indicated in patients with
MM, with or without detectable osteolytic bone lesions on
conventional radiography, who are receiving antimyeloma
therapy as well as in patients with osteoporosis or osteopenia
resulting from myeloma.4 Although the main reason for their
indication is that bisphosphonates prevent skeletal-related
events, there are also controversial data suggesting that zole-
dronic acid (ZA) has an anti-myeloma effect. This hypothe-
sized antitumor effect is based on findings in pre-clinical stud-
ies,5-7 reproduced in small series of patients,8 and subanalyses
of clinical trials,9,10 particularly, the large MRC-IX trial9 con-
ducted in newly diagnosed patients treated with either
chemotherapy (CVAB) or thalidomide-based therapy (CTD),
who were assigned to receive either ZA or clodronate. The
ZA-treated group had significantly longer progression-free sur-
vival and overall survival compared with the clodronate-treat-
ed group. However, this study included several randomiza-
tions, such as thalidomide maintenance, and it is not easy to
dissect the real anti-tumor effect from other beneficial anti-
myeloma effects of ZA treatment. Moreover, in patients with
smoldering MM, treatment with bisphosphonates did not
delay transformation into symptomatic disease although it
was associated with a reduction in the onset of skeletal-related
events.11-16 Accordingly, the real anti-tumor effect of bisphos-
phonates remains to be elucidated. Patients at biochemical
relapse, in whom the standard of care is to delay treatment
until symptoms emerge, represent an ideal group to investi-
gate the anti-myeloma effect of ZA. 
The AZABACHE trial was conducted by the Spanish
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This study analyzed the anti-myeloma effect of zoledronic acid monotherapy by investigating patients at the time
of asymptomatic biochemical relapse. One hundred patients were randomized to receive either zoledronic acid (4
mg iv/4 weeks, 12 doses) (n=51) or not (n=49). Experimental and control groups were well balanced for disease
and prognostic features. Zoledronic acid did not show an antitumor effect according to changes in M-component.
However, there were fewer symptomatic progressions in the experimental group than in the control group (34 ver-
sus 41, respectively; P=0.05) resulting in a median time to symptoms of 16 versus 10 months (P=0.161). The median
time to next therapy was also slightly longer for the treated group than the untreated, control group (13.4 versus
10.1 months), although the difference was not statistically significant (P=0.360). The pattern of relapses was dif-
ferent for treated versus control patients: progressive bone disease (8 versus 20), anemia (24 versus 18), renal dysfunc-
tion (1 versus 2), and plasmacytomas (1 versus 1, respectively). This concurred with fewer skeletal-related events in
the treated group than in the control group (2 versus 14), with a projected 4-year event proportion of 6% versus 40%
(P<0.001). In summary, zoledronic acid monotherapy does not show an antitumor effect on biochemical relapses
in multiple myeloma, but does reduce the risk of progression with symptomatic bone disease and skeletal compli-
cations. This trial was registered in the ClinicalTrials.gov database with code NCT01087008
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Myeloma Group (GEM/PETHEMA) in order to evaluate
whether treatment with ZA delays the time to next ther-
apy (TNT) in patients with MM in biochemical relapse,
compared to the standard management with observation
only. 
Methods
Trial design
In 2010, GEM/PETHEMA activated the “Analysis of Zoledronic
Acid therapy in MM in BioCHEmical relapses” (AZABACHE) trial.
This randomized, prospective, open label, phase IV trial included
MM patients in asymptomatic biochemical relapse after a prior
response to standard therapy. Patients were randomly distributed
into two groups: (i) the experimental group, in which patients
received ZA, and (ii) the control group in which patients did not
receive any treatment. Patients in the experimental group received
zolendronic acid, 4 mg in a 15-minute intravenous infusion every
4 weeks, for a total of 12 doses, plus standard supportive care; the
control group received only supportive care. The trial and all pro-
cedures were performed in accordance with the Helsinki
Declaration and were reviewed and approved by the Spanish
National Agency and the Ethics Committees of all the centers
involved.
Inclusion and exclusion criteria
All patients had to meet the following inclusion criteria: (i) 18
years of age or older; (ii) confirmed biochemical relapse of MM
after an initial response, without symptoms derived from the dis-
ease and (iii) signed informed consent to participation in the trial.
Relapse was defined according to the IMWG criteria of 2006.2
Patients treated for any symptom of myeloma-related organ or tis-
sue impairment or who had received bisphosphonates in the pre-
ceding 3 months were excluded; this meant that most patients had
had a prior response longer than 24 months, which is the usual
time that bisphosphonates are given in Spanish trials.17
Variables for evaluation
The main end-point was TNT, which was calculated as the time
that elapsed between inclusion in the protocol, and the moment at
which new antimyeloma therapy was initiated based on the
appearance of a clinical relapse or death from any cause. The
appearance of a significant paraprotein relapse was not considered
as a clinical relapse but it was qualified as a cause for initiating
anti-myeloma when considering the TNT.3
Other end-points for evaluation were: (i) response rate during
the follow-up period (12 months of therapy or follow-up, or until
drop-out of the trial) according to the IMWG criteria;3 (ii) time to
clinical symptoms, defined as the time between inclusion in the
trial and the development of a clinical (CRAB) relapse;3 and (iii)
time to a skeletal-related event, defined as the time between inclu-
sion in the trial and the occurrence of any the following: bone frac-
ture (vertebral and non-vertebral), requirement for bone radiother-
apy, requirement for bone surgery, or hypercalcemia. The pres-
ence of osteonecrosis of the jaw and/or renal dysfunction was
carefully assessed throughout the treatment and follow-up peri-
ods. In addition, we evaluated the characteristics of symptomatic
relapses occurring in patients included in the trial (i.e. type of
CRAB) and associated clinical and biological variables. All patients
were monitored every 4 weeks for disease response, CRAB symp-
toms and adverse events. Recommendations for the safe use of
bisphosphonates, as stated in the commercial labeling of ZA, were
specifically followed, as were the recommendations of the
European Myeloma Network.17,18
A more detailed description of the methods can be found in the
Online Supplement.
Results
Patients’ baseline characteristics and protocol 
compliance 
From June 2010 to July 2012, 100 patients were recruited:
51 in the ZA group and 49 in the control group. The base-
line characteristics of the patients at the moment of inclu-
sion in the trial are shown in Table 1. Their median age was
68 years (range, 40-87). The M-component was IgG in 72%
of cases, and IgA in 25% of cases; 3% had only light-chain
MM. The biochemical relapse occurred after one, two or
three or more lines of therapy in 67%, 22% and 11% of
cases, respectively. Prior treatment included transplant in
66% of patients, bortezomib in 53% and immunomodula-
tory drugs in 32%. Bone lesions were present at the initial
diagnostic X-ray skeletal survey in 68% of patients. Overall,
32% of patients had developed one to three skeletal-related
events prior to trial inclusion. The median time between the
biochemical relapse and inclusion in the protocol was 4
months (range, 1-21). The median bone marrow plasma cell
infiltration was 3% (range, 0-96%) by morphology.
Fluorescence in situ hybridization/cytogenetic findings were
abnormal in 52% of cases: t(11;14) in 19%, Rb deletion
(alone) in 17%, del(p53) in 8%, t(4;14) in 4% and t(14;x) in
4%. Hemoglobin, creatinine, and calcium levels were nor-
mal (as per protocol). β2-microglobulin and C-reactive pro-
tein levels were also normal in all cases. Patients in the ZA-
treated and control groups were well balanced for prognos-
tic features, prior response, and time from diagnosis to
inclusion in the trial (Table 1).
Regarding protocol compliance, 44 patients completed
the 12 visits for the interventional phase of the trial and
four terminated before completion due to patients’ refusal
to continue participation (n=2) and development of other
diseases (n=2). The remaining 54 patients stopped the
trial because of progression before 12 months (n=52), tox-
Table 1. Characteristics of the patients.
                                                                     Control         ZA          P
                                                                     group        Group
                                                                       (n=49)       (n=51)         
Female gender                                                           53%              41%         0.316
More than one prior line of therapy                      41%              26%         0.103
High-risk cytogenetics                                               17%              15%         0.876
Prior osteolytic bone lesions                                  73%              63%         0.288
Prior skeletal-related event                                     31%              33%         0.947
Prior transplant                                                           57%              75%         0,091
Prior bortezomib                                                        57%              49%         0,431
Prior immunomodulatory drug                                43%              22%         0.032
Age >65 years                                                              63%              62%         0,929
M-component >10 g/L                                               89%              92%         0.711
C-reactive protein >1 mg/dL                                   22%              24%         1.000
β2-microglobulin >3 mg/L                                        33%              36%         1.000
Hemoglobin >12 g/dL                                                81%              76%         0,638
High lactate dehydrogenase                                     8%                9%          1.000
Time from diagnosis to recruitment >5 years    29%              35%         0.469
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icity (n=1, osteonecrosis of the jaw) and initiation of cyto-
toxic therapy due to a significant paraprotein relapse
(n=1). The distribution of patients in the trial is summa-
rized in Figure 1.
With a median follow-up for surviving patients of 38
months, TNT since inclusion in the study was 10.9 months
for the overall series of patients (Figure 2A). The reason for
starting therapy was the development of symptomatic dis-
ease in all but three patients in whom therapy was started
because of a significant paraprotein relapse in the absence
of symptoms. The median time to clinical symptoms was
11.3 months, which was essentially the same as the TNT
(Figure 2A). Time to a new skeletal-related event was not
reached during the follow-up of the trial, with a projected
percentage of skeletal-related events of 21.5% at 4 years.
The median overall survival from inclusion in the trial was
47 months (Figure 2B).
Efficacy
Myeloma responses were not observed during the treat-
ment with ZA and, therefore, no antitumor effect of ZA
therapy was demonstrated. Of note, two patients in the
control group experienced small M-component reductions
that were not sustained over time. However, the proportion
of patients progressing to symptomatic disease was lower
in the ZA-treated group (n=34, 67%) than in the control
group (n=41, 83%, P=0.05), although this only partially
translated into differences in the survival curves.
Accordingly, TNT was slightly longer for the ZA-treated
group than the control group (median: 13.4 months versus
Figure 2. (A) Time to next therapy and time to clinical symptoms of the global series of patients. (B) Overall survival overlapped with the time
to the next skeletal-related event (SRE) for all patients.
Figure 1. Flow-chart of the patients’ distribution through the trial.
A B
10.1 months), with 3-year projected treatment-free rates of
22% versus 16%, respectively (P=0.360) (Figure 3A). The
behavior of time to clinical symptoms was similar, with the
median being 16 versus 10 months in the ZA and control
groups, respectively, and the 3-year time free of symptom
rates being 32% versus 24%, respectively (P=0.203) (Figure
3B). The pattern of the clinical relapses showed relevant dif-
ferences according to trial group. In the control group 20
patients developed more advanced bone disease (15 cases
with new bone lesions, 3 cases with spinal cord compres-
sion, and 2 cases of hypercalcemia), 18 patients had anemia,
two developed renal dysfunction, and one developed a plas-
macytoma. In the ZA-treated group, progressive disease
was manifested by anemia (24 patients), new bone lesions
(8 patients), renal dysfunction (1 patient) and
extramedullary disease (1 patient) (P<0.01) (Table 2).
Overall, progressive bone disease (osteolytic bone lesions,
spinal cord compression and hypercalcemia) was observed
in 16% of patients in the experimental group versus 41% in
the control group (P=0.005). After the study, patients with
progression to symptomatic disease received subsequent
rescue therapy which usually included continuation with
bisphosphonates. The 25 patients who did not develop clin-
ical symptoms continued with ZA therapy in 13 cases or no
longer received therapy in 12 cases, according to their clini-
cians’ decisions.
As far as concerns skeletal-related events, 16 events were
reported in the trial (five vertebral fractures, four non-verte-
bral fractures, two cases of hypercalcemia, three cases of
skeletal cord compressions, and two cases of radiotherapy
or bone surgery requirement) and they were related with an
important number of overall deaths (11/37). Consequently,
the actuarial 3-year overall survival rate for patients suffer-
ing a new skeletal-related event was 31% while it was 66%
for patients free of new skeletal-related events (P=0.047).
Interestingly, only two out of 14 skeletal-related events
appeared in the ZA group. Consequently, the use of ZA
was associated with significantly fewer skeletal-related
events than simple observation. The projected 4-year risk of
skeletal-related events was 6% for patients in the ZA group
versus 40% in the control group (P<0.001) (Figure 3C).
A trend to a longer overall survival was observed for the
ZA group versus the control group, with 3-year projected
overall survival rates of 73% versus 46%, respectively
(Figure 3D). Interestingly, the effects on overall survival
were more evident in those patients who had more
advanced bone disease. There were 68 patients with prior
osteolytic lesions (32 treated and 36 not treated with ZA)
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Figure 3. Differences in survival according to the treatment group. (A) Time to the next therapy. (B) Time to clinical symptoms. (C) Time to the
next skeletal related event (SRE). (D) Overall survival. Solid line, experimental group; dashed line, control group.
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and among these patients the 3-year overall survival rate
was higher for patients treated with ZA than for those not
treated with the bisphosphonate (61% versus 32%,
P=0.064). In addition, there were 36 patients who had had
skeletal-related events before inclusion in the trial, and the
3-year overall survival rate was higher among treated
patients (n=18) than untreated ones (n=18) (69% versus
20%, respectively; P=0.016).
Toxicity
All patients were evaluated for toxicity. Globally, 29
adverse events were recorded in 17 patients (8 in the ZA
group and 9 in the control group) (Table 3): 12 grade 1, nine
grade 2 and eigth grade 3 events. There were no grade 4
adverse events and there were no significant differences in
the frequency of adverse events between the experimental
and control groups (Table 3). Eight adverse events in six
patients (3 in each group) were considered severe. All serious
adverse events were considered related to the underlying dis-
ease and resolved with appropriate therapy with the excep-
tion of osteonecrosis of the jaw that was related to ZA
administration and caused trial discontinuation. Two patients
in the control group developed renal problems. No patient
developed any thromboembolic event during the trial.
Discussion
Intravenous bisphosphonates are the standard of care
for the prevention of skeletal-related events and treatment
of hypercalcemia in patients with MM.4 In addition, some
randomized trials have shown clinical benefits for bispho-
sphonates in these patients when they are administered
during cytotoxic therapy.8-10 These results and some pre-
clinical studies argue in favor of an antimyeloma effect for
the most potent bisphosphonates. The present random-
ized trial does not support a direct antitumor effect of
intravenous ZA when administered as single therapy in
myeloma patients at biochemical relapse since no reduc-
tion in M-component or prolongation in TNT was
observed. However, considering that clinical progressions
in the control group were mainly due to bone disease, we
may counter-argue in favor of the use of ZA in patients at
biochemical relapse. 
The possible antitumor effect of bisphosphonates has
long been evaluated in MM19,20 and other tumors.21 Since
the initial observation that intravenous pamidronate could
prolong the overall survival of some subsets of MM
patients,22 several groups have highlighted different direct
and indirect mechanisms by which bisphosphonates can
exert an antitumor effect, especially in MM.5-7,23 The
hypothesized antitumor effect was partially confirmed in
vivo in two different clinical trials, in which the use of ZA
acid resulted in a higher rate of response,8 and longer pro-
gression-free survival and overall survival.8,9 More specifi-
cally, in the MRC IX trial, in which almost 2,000 patients
were treated, the use of ZA extended the overall survival
by 5.5 months and progression-free survival by 2.0
months. However, in all trials in which bisphosphonates
have demonstrated some survival advantage,8,9,22 the
Table 2. Characteristics of progressive disease by trial arm.
Type of progression Control group ZA group Total
No symptomatic progression 8 16% 17 33% 25
Anemia (hemoglobin decrease ≥2 g/dL) 18 38% 24 47% 42
New lytic lesions or increase of prior lytic lesions* 15 31% 8 16% 23
Spinal cord compression* 3 6% 0 0% 3
Hypercalcemia (>11.5 mg/dL)* 2 4% 0 0% 2
Development of plasmacytoma 1 2% 1 2% 2
Serum creatinine ≥2 mg/dL 2 4% 1 2% 3
Total 49 51 100
(*) Clinical progression with worsening bone disease: new or increasing bone lesions, spinal cord compression or hypercalcemia: 41% vs. 16%, P=0.005.
Table 3. Adverse events recorded by trial arm.
ZA group (n=51) Control group (n=49)
Grade 1 Grade 2 Grade 3 Total Grade 1 Grade 2 Grade 3 Total
N. % N. % N. % N. % N. % N. % N. % N. %
Bone pain 2 4 1 2 0 0 0 0.0 3 6 1 2 0 0 4 8.2
Respiratory infection 0 0 1 2 1 2 2 5.1 3 6 3 6 1 2 7 14.2
Neuropathy 1 2 0 0 0 0 1 2.0 2 4 0 0 0 0 2 4.0
Renal dysfunction 1 2 0 0 0 0 1 2.0 0 0 1 2 1 2 2 4.0
Transient ischemic attack 1 2 0 0 0 0 1 2.0 0 0 0 0 0 0 0 0.0
Aortic lesion 0 0 0 0 0 0 0 0.0 0 0 0 0 1 2 1 2.0
Angina pectoris 0 0 0 0 0 0 0 0.0 0 0 0 0 1 2 1 2.0
Retinal detachment 0 0 0 0 1 2 1 2.0 0 0 0 0 0 0 0 0.0
Genital surgery 0 0 0 0 1 2 0 0.0 0 0 0 0 0 0 0 0.0
Choledocholithiasis 0 0 1 2 0 0 0 0.0 0 0 0 0 0 0 0 0.0
Osteonecrosis of the jaw 0 0 0 0 1 2 1 2.0 0 0 0 0 0 0 0 0.0
assessment of the antitumor effect of these drugs was
complicated by the antitumor effect of the chemotherapy
or novel antimyeloma drugs that were given at the same
time. Several studies have also evaluated the antitumor
effect of bisphosphonate monotherapy in patients with
asymptomatic/smoldering MM.11-16 Although these studies
demonstrated some benefit of bisphosphonates on bone
resorption, no clear tumor responses or benefits in terms
of progression-free or overall survival were observed.
Patients with smoldering MM probably do not constitute
the ideal target population for such studies because, given
their low rate of progression,24 a large number of patients
and long follow up would be needed to demonstrate a sur-
vival benefit for a drug that would have only a minor anti-
tumor activity, if any.
In our study, we decided to evaluate the potential anti-
tumor efficacy of ZA as a single agent with a similar
approach, but targeting a different patient population
(those with biochemical relapses) for three reasons. First,
biochemical relapses are very frequent.25,26 Second, most
patients who have biochemical relapses very soon require
therapy; Fernandez-Larrea et al. recently reported that
most such patients need therapy at a median time of 5.6
months after transplantation,27 which is concordant with
the estimations from the VISTA trial in non-transplant
candidates upon comparing time to progression and
TNT.28 Third, there is no universal consensus on how to
treat these patients and many physicians prefer not to
treat until symptoms emerge.29
As mentioned above, in this study the use of ZA as single
therapy was not directly associated with an antitumor effect,
since no reductions in the M-component were seen.
However, the rate of progression was lower in the ZA group
than in the untreated group (67% versus 87%, P=0.05). This
translated into trends, albeit not statistically significant, to
longer time to clinical symptoms and TNT (13.4 and 16
months in the ZA group versus 10.1 and 10 months in the
control group, respectively). It is important to highlight that
TNT was 10 months in the control group, which is longer
than the expected 5-6 months.27,28 This can be explained
because patients included in this trial were a selected low-risk
population, since they were patients in biochemical relapse
who had had a previous long response (longer than 24
months, the time that Spanish protocols maintain bisphos-
phonate therapy). This selection could partially explain why
the differences between the treatment and control groups
were not as high as predicted. An important observation was
the significantly different pattern of symptomatic progres-
sion observed in patients in the experimental group com-
pared to those in the control group, since in the latter group
myeloma mainly progressed with bone disease, while ZA-
treated patients mainly progressed with other symptoms,
such as anemia. This different pattern could be related to the
marginal benefits observed in overall survival for ZA-treated
patients in the absence of clear improvements in time to clin-
ical symptoms. A similar discrepancy was also observed in
the MRC IX trial, in which the increase in overall survival
with ZA therapy was more pronounced than the increase in
progression-free survival.9 It is conceivable that the low inci-
dence of skeletal-related events and other potential MM
complications could be the basis for this more pronounced
benefit of ZA therapy on the overall survival.
Development of skeletal-related events is an important
complication of MM and results in high morbidity, mortal-
ity, and costs.30-33 In this study, the use of ZA resulted in a
very important reduction of skeletal-related events with
respect to the rate in the control group (4% versus 33%),
with 4-year accumulated skeletal-related event rates of
6% versus 40%, respectively (P<0.001). This supports the
findings of several other studies in which the use of bis-
phosphonates always translated into a reduction of skele-
tal-related events.8,9,11-16,22 This reduction in skeletal-related
events could also help to explain why the overall survival
was marginally favored by the use of ZA, with a more
pronounced effect in patients with bone disease or skele-
tal-related events, as the MRC trial had already demon-
strated.9 However, the number of patients and differences
in this study are limited, which should be taken into con-
sideration when interpreting the results. New imaging
techniques could identify patients with no relevant bone
disease and low expectations of benefit from bisphospho-
nate therapy, but a global interpretation of our findings
suggests that ZA treatment has an evident clinical benefit
for MM patients in the setting of asymptomatic biochem-
ical relapses. Since ZA therapy is not an expensive strategy
and it is associated with very few adverse events, it could
be considered as a change in the clinical standard of care
of patients with asymptomatic biochemical relapses, in
favor of a more active approach than the current, com-
monly used, watch-and-wait strategy. Accordingly, we
recommend the use of ZA therapy in patients under bio-
chemical relapses for at least 12 months; in the case of
development of symptomatic disease, bisphosphonate use
should follow the rules of the rescue protocol, while in
those patients who remain asymptomatic after 1 year of
ZA treatment, therapy should be maintained following
the current recommendations of the IMWG, which favor
the use of bisphosphonate therapy until progression for
patients who are not in complete or very good partial
response.4
In summary, this randomized trial demonstrates that
early monotherapy with ZA reduces the risk of progres-
sion with symptomatic bone disease and minimizes the
incidence of skeletal-related events without significant
toxicity in MM patients with asymptomatic biochemical
relapse, and accordingly it should be considered as a new
standard of care for this group of patients.
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